Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.17
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -0.06% | 142.59% | |||
| Gross Profit | -112.72% | -120.01% | |||
| SG&A Expenses | 19.42% | -0.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.87% | 21.30% | |||
| Operating Income | -48.43% | 10.21% | |||
| Income Before Tax | -16.28% | 4.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.45% | -1.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.45% | -1.03% | |||
| EBIT | -48.43% | 10.21% | |||
| EBITDA | -48.51% | 10.22% | |||
| EPS Basic | 43.03% | 53.04% | |||
| Normalized Basic EPS | 40.02% | 55.40% | |||
| EPS Diluted | 43.03% | 53.04% | |||
| Normalized Diluted EPS | 40.02% | 55.40% | |||
| Average Basic Shares Outstanding | 93.87% | 115.12% | |||
| Average Diluted Shares Outstanding | 93.87% | 115.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||